Novartis axing 1,400 US sales jobs due to product changes

Share this article:
Effective January 1, Novartis will reduce its US field force by 1,400 positions, the firm said, as it braces for patent expiries and shifts resources for product launches.

The layoffs, expected to cost about $85 million according to a company statement, will come in the General Medicines field force. The restructuring does not affect oncology or the Sandoz generics unit, spokesperson Julie Masow told MM&M.

Novartis said its business is changing due to pending patent expirations and pipeline products, new launches expected within primary care and growth within specialty care. The Swiss firm is losing Femara (cancer) in 2011, Diovan (hypertension) in 2012 and Gleevec (cancer) in 2015 to generics.

Recent launches have included Gilenya, the first oral disease-modifying drug for multiple sclerosis, which won approval in September and launched last month. Also this year, Sandoz released a difficult-to-copy version of antithrombotic Lovenox. Pipeline products are in various stages of development.

“[Novartis] has a robust pipeline and the future growth potential for our organization remains strong,” said Andy Wyss, head of Novartis Pharma North America and president of Novartis Pharmaceuticals Corp. The changes “will enable us to focus our resources on key launch products and capture opportunities in both primary care and specialty medicines.”

Fellow Swiss pharma Roche recently detailed plans to cut 4,800 jobs, with another 1,500 positions being either transferred or outsourced to third parties.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...